AltPep is developing a highly-selective platform that utilizes custom-designed peptides to target and neutralize α-sheet toxic oligomers, which are early molecular triggers of amyloid diseases such as Alzheimer’s and Parkinson’s. Their approach enables early detection and disease-modifying treatment, aiming to alter the progression of these conditions before symptoms manifest.
Funding
$76.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIFounders
Product
Problem
Amyloid diseases, such as Alzheimer's and Parkinson's, are characterized by the formation of toxic oligomers that trigger disease progression, often before noticeable symptoms appear. Current diagnostic and therapeutic approaches lack the ability to effectively target and neutralize these early molecular triggers. This results in delayed intervention and limited success in altering the course of these debilitating conditions.
Solution
AltPep is developing a platform based on custom-designed peptides that selectively target and neutralize α-sheet toxic oligomers, which are early molecular triggers of amyloid diseases. This approach enables both early detection and disease-modifying treatment by intervening at the initial stages of disease development. AltPep's platform aims to shift the paradigm in amyloid disease management by providing tools to identify and address the underlying causes before irreversible damage occurs. The platform consists of SOBIN therapeutics, designed to neutralize toxic soluble oligomers, and SOBA diagnostics, highly sensitive blood tests for early disease detection. By targeting the α-sheet structure, AltPep's technology offers a novel strategy to combat a range of amyloid diseases.
Target Audience
The primary target audience includes researchers and clinicians focused on early detection and treatment of amyloid diseases, as well as pharmaceutical companies developing disease-modifying therapies.
Features
- Custom-designed synthetic peptides that selectively bind to α-sheet toxic soluble oligomers.
- SOBIN therapeutics to neutralize toxic soluble oligomers associated with amyloid diseases.
- SOBA diagnostics: Highly sensitive blood tests for the early detection of amyloid diseases.
- Platform applicable to Alzheimer's, Parkinson's, and other amyloid diseases.
- Designed to target and neutralize toxic oligomers early in disease progression.